Daily high-dose interferon suppresses viremia in patients with chronic hepatitis C without a previous sustained response to standard treatment

Jb, Gross; Brandhagen, DJ; Poterucha, JJ; Gossard, AA; Dd, Douglas

doi:10.1016/s0016-5085(98)85065-8

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A longer duration of therapy reduces relapse and achieves sustained response rates of more than 20% [3,4]. Results with higher doses as either induction or longterm therapy are controversial, but there is not yet sufficient evidence to suggest that long-term results are improved [13][14][15][16]. It does, however, appear that high-o daily-dose induction may be useful in some patients, such as those with high pretreatment viral levels [17].…”

Section: Interferon and Ribavirin As Single Agentsmentioning

confidence: 99%

Treatment of chronic hepatitis C: Impact of combination therapy

Davis

1999

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Interferon as a single agent results in normalization of the serum alanine aminotransferase (ALT) levels, loss of detectable serum hepatitis C virus RNA, and histologic improvement in approximately 40% of patients. However, regardless of the duration of initial therapy, most patients relapse within the first few months after the drug is stopped, and only a small proportion have a sustained response. Ribavirin is a nucleoside analogue that is known to have in vitro activity against a number of both RNA and DNA viruses. As a single agent, oral ribavirin treatment transiently lowers serum ALT values into the normal range in about 40% of cases of chronic hepatitis C, but it does not affect the level of viremia. However, when given in combination with interferon for 6 to 12 months, ribavirin results in a sustained normalization of serum ALT levels and loss of detectable hepatitis C virus RNA in 30% to 40% of previously untreated patients. Retreatment of interferon relapsers with the combination of interferon and oral ribavirin for 6 months results in a sustained viral-negative response in about half of patients. Thus far, there is little evidence that combination therapy is effective in patients in whom ALT fails to normalize and who have lost hepatitis C virus RNA during a previous treatment course (nonresponders). Studies are ongoing in this group.

show abstract

Section: Interferon and Ribavirin As Single Agentsmentioning

confidence: 99%

Treatment of chronic hepatitis C: Impact of combination therapy

Davis

1999

Curr Gastroenterol Rep

View full text Add to dashboard Cite

show abstract

Viral, host and interferon‐related factors modulating the effect of interferon therapy for hepatitis C virus infection

Vierling

Redeker

2001

Journal of Viral Hepatitis

View full text Add to dashboard Cite

The estimated prevalence of hepatitis C virus infection in the US is approximately 1.8%. Although interferon monotherapy and combination therapy of interferon with ribavirin represent mainstay for treating HCV infection, the rate of sustained virologic response remains suboptimal. The growing evidence suggested that the clinical sequence and treatment response of chronic hepatitis C are determined by a dynamic, complex tripartite relationship among HCV infection, the host immune response, and the effect of different interferon regimens. The treatment response is associated with various viral factors including the pretreatment viral level, dynamic change of viral level during treatment, viral genotype quasispecies and nucleotide mutation in nonstructural protein 5A of hepatitis C virus. Host factors that may affect treatment response include age, gender, race, HLA alleles and the host immune responses. Interferon regimens, including type, dose, frequency and duration of treatment and combination of interferon with other anti-HCV agents also alter the therapeutic response. Understanding these complicated interaction may provide better insights into the mechanism(s) of interferon response, leading to more effective clinical application of interferon therapy.The response to both IFN monotherapy and combination therapy of IFN and ribavirin varies among different HCV genotypes [39,47±51]. The frequency of long-term normal-Ó

show abstract

Daily high-dose interferon suppresses viremia in patients with chronic hepatitis C without a previous sustained response to standard treatment

Cited by 2 publications

References 0 publications

Treatment of chronic hepatitis C: Impact of combination therapy

Treatment of chronic hepatitis C: Impact of combination therapy

Viral, host and interferon‐related factors modulating the effect of interferon therapy for hepatitis C virus infection

Contact Info

Product

Resources

About